Kymera Therapeutics (NASDAQ:KYMR) Rating Lowered to Sell at Wall Street Zen

Kymera Therapeutics (NASDAQ:KYMR) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other equities analysts have also recently issued reports on KYMR. Oppenheimer raised their price objective on shares of Kymera Therapeutics from $67.00 to $120.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. Citigroup upped their target price on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Morgan Stanley restated an “overweight” rating and issued a $123.00 price target on shares of Kymera Therapeutics in a research report on Thursday, February 26th. Stephens lifted their price objective on Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a research note on Monday, March 2nd. Finally, Barclays upped their price objective on Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a report on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $119.50.

Kymera Therapeutics Trading Down 0.0%

Kymera Therapeutics stock opened at $83.49 on Friday. Kymera Therapeutics has a 1 year low of $19.44 and a 1 year high of $103.00. The company has a market cap of $6.82 billion, a PE ratio of -22.69 and a beta of 2.20. The company’s 50-day moving average is $78.80 and its two-hundred day moving average is $67.14.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The business had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm’s quarterly revenue was down 60.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.88) EPS. Research analysts forecast that Kymera Therapeutics will post -2.79 EPS for the current year.

Insider Buying and Selling

In related news, insider Jared Gollob sold 4,895 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $85.30, for a total value of $417,543.50. Following the completion of the sale, the insider owned 117,134 shares in the company, valued at $9,991,530.20. This represents a 4.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Bruce N. Jacobs sold 4,895 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $85.30, for a total value of $417,543.50. Following the sale, the chief financial officer directly owned 232,588 shares in the company, valued at $19,839,756.40. The trade was a 2.06% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 407,391 shares of company stock valued at $36,650,485. 16.01% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. US Bancorp DE increased its stake in Kymera Therapeutics by 9.8% in the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after buying an additional 166 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Kymera Therapeutics by 9.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock worth $156,000 after buying an additional 248 shares during the last quarter. Larson Financial Group LLC boosted its stake in shares of Kymera Therapeutics by 36.9% during the 4th quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after buying an additional 287 shares during the last quarter. State Board of Administration of Florida Retirement System grew its holdings in shares of Kymera Therapeutics by 3.3% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 12,655 shares of the company’s stock valued at $985,000 after acquiring an additional 410 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after acquiring an additional 424 shares in the last quarter.

More Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near‑term loss forecasts (small EPS improvements across Q1–Q4 2026), kept a “Buy” rating and reiterated a $134 price target — this reinforces constructive analyst sentiment and supports buying interest. Read More.
• Positive Sentiment: UBS and several peers have raised price targets (UBS to $128, Barclays/Oppenheimer/Mizuho also higher), signaling consensus analyst optimism around Kymera’s pipeline progress as a medium‑term catalyst. Read More.
• Positive Sentiment: Another outlet reported a price‑target bump to $100 — additional upward target revisions help underpin sentiment even as valuation remains tied to clinical milestones. Read More.
• Positive Sentiment: Coverage highlights a healthy cash runway (~$1.6B reported) and upcoming program milestones (KT‑579 data in 2H26; KT‑621 Phase 2b readouts in 2027) that are the primary value drivers for this clinical‑stage biotech. Read More.
• Neutral Sentiment: Technical/contextual note — KYMR is trading above its 200‑day moving average with elevated volatility (beta ~2.2); analyst average targets remain well above current levels, which can amplify momentum in either direction. Read More.
• Negative Sentiment: Large director sale: Director Bruce Booth sold 81,866 shares (~$7.38M at ≈$90), a material single‑day disposal that can be perceived as profit‑taking and may cap short‑term upside. Read More.
• Negative Sentiment: Multiple senior insiders (CFO Bruce Jacobs, COO Jeremy Chadwick, Jared Gollob and others) disclosed sales across March 2–4 at roughly $85–$89, each trimming holdings by a few percent — repeated insider selling increases short‑term supply and investor caution. Read More.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.